Loading…
Caris Life Sciences, Inc. is projected to rise to $17.17 by 2027, a +7% move from its current price of $16.09. CAI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $15.69 | $16.10 | $16.51 | +0.05% |
| Aug 2 | $15.54 | $16.11 | $16.70 | +0.10% |
| Aug 3 | $15.42 | $16.11 | $16.84 | +0.15% |
| Aug 4 | $15.32 | $16.12 | $16.96 | +0.20% |
| Aug 5 | $15.24 | $16.13 | $17.07 | +0.25% |
| Aug 6 | $15.16 | $16.14 | $17.17 | +0.30% |
| Aug 7 | $15.10 | $16.15 | $17.27 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.10 | $16.15 | $17.27 | +0.35% |
| Week 2 | $14.73 | $16.20 | $17.82 | +0.70% |
| Week 3 | $14.47 | $16.26 | $18.27 | +1.06% |
| Week 4 | $14.26 | $16.32 | $18.66 | +1.41% |
| Week 5 | $14.09 | $16.37 | $19.03 | +1.77% |
| Week 6 | $13.94 | $16.43 | $19.37 | +2.12% |
| Week 7 | $13.80 | $16.49 | $19.70 | +2.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Caris Life Sciences, Inc. (CAI) trades at $15.56 per share and has a market cap of $4.4B. The company is ranked 1378 in market position.
The near-term price picture places CAI in a zone where the 30-day range runs from $12.72 to $19.03, with current price near support at $15.56 and facing resistance at $18.75.
Looking ahead, the year-by-year forecast shows the average price rising over time—from $15.56 in 2026 to $83.13 in 2050—accompanied by rising investor expectations. The forecast also reveals varying min/max targets and positive ROI deep into the horizon, with sentiment shifting toward bullish in the later years.
A major floor 16.9% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 16.5% above — a clean break opens room to run.
A major ceiling 32.0% above — clearing it would confirm fresh momentum.
Key CAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.68 | Buy | $15.79 | Buy |
| MA 10 | $15.72 | Buy | $15.93 | Buy |
| MA 20 | $16.55 | Sell | $16.35 | Sell |
| MA 50 | $16.87 | Sell | $17.02 | Sell |
| MA 100 | $17.72 | Sell | $18.31 | Sell |
| MA 200 | $21.72 | Sell | $20.90 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.11 | Neutral |
| Stoch RSI (14) | 67.75 | Neutral |
| CCI (20) | -36.68 | Neutral |
| Williams %R (14) | -65.87 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -5.07 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 34.13 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -1.51 | Sell |
| Ultimate (7,14,28) | 52.78 | Neutral |
| Momentum (10) | -0.39 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 15.74 | Buy |
| ADX (14) | 15.21 | Neutral |
| ATR (14) | 0.36 | Info |
Near term, the market sentiment is bearish with RSI(14) at 40.
The technicals show the 50-day simple moving average at $16.93 and the 200-day simple moving average at $22.35, placing the price between near-term support and longer-term resistance. The stock is shown with a defined support at $15.56 and a resistance at $18.75.
The 30-day price range is $12.72 to $19.03, highlighting a broad swing in the near term and outlining potential downside risk toward the support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.55 | $16.09 | $21.13 | 0% | Neutral | |
| $13.51 | $17.17 | $23.19 | +7% | Neutral | |
| $14.38 | $18.90 | $26.63 | +17% | Neutral | |
| $16.19 | $21.86 | $31.83 | +36% | Bullish | |
| $18.00 | $24.91 | $37.27 | +55% | Bullish | |
| $19.53 | $27.62 | $42.33 | +72% | Bullish | |
| $20.08 | $28.99 | $45.38 | +80% | Bullish | |
| $20.54 | $30.24 | $48.25 | +88% | Bullish | |
| $20.32 | $30.47 | $49.49 | +89% | Bullish | |
| $20.64 | $31.50 | $52.01 | +96% | Bullish | |
| $28.95 | $47.92 | $84.70 | +198% | Bullish | |
| $47.99 | $91.57 | $178.62 | +469% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.55 | $16.09 | $18.78 | +0.00% |
| August 2026 | $13.85 | $16.30 | $19.68 | +1.32% |
| September 2026 | $14.17 | $16.84 | $20.64 | +3.30% |
| October 2026 | $14.01 | $16.78 | $20.82 | -0.37% |
| November 2026 | $13.63 | $16.44 | $20.59 | -2.05% |
| December 2026 | $13.78 | $16.72 | $21.13 | +1.71% |
Click any year to see its month-by-month CAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAI price prediction for 2026 points to an average of $16.09 (low $14.55, high $21.13) — a potential gain of 0% on today's $16.09. Price action looks broadly range-bound.
In 2027, CAI is projected to trade between $13.51 and $23.19, averaging $17.17 — a potential gain of +7% from today's $16.09. That is up +7% on the projected 2026 average. A consolidation phase looks the most probable path here.
Caris Life Sciences, Inc.'s 2028 outlook centres on $18.90, within a $14.38 to $26.63 range. That is up +10% on the projected 2027 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2029, CAI could reach as high as $31.83, with a base case around $21.86 and support toward $16.19 — roughly +36% from $16.09. Buyers look set to stay in control over this stretch.
Expect CAI to range from $18.00 to $37.27 through 2030. The $24.91 average target implies a +55% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The CAI price prediction for 2031 points to an average of $27.62 (low $19.53, high $42.33) — a potential gain of +72% on today's $16.09. Buyers look set to stay in control over this stretch.
In 2032, CAI is projected to trade between $20.08 and $45.38, averaging $28.99 — a potential gain of +80% from today's $16.09. That is up +5% on the projected 2031 average. Momentum favours further upside here.
Caris Life Sciences, Inc.'s 2033 outlook centres on $30.24, within a $20.54 to $48.25 range. That is up +4% on the projected 2032 average. That marks a +88% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CAI could reach as high as $49.49, with a base case around $30.47 and support toward $20.32 — roughly +89% from $16.09. Momentum favours further upside here.
Expect CAI to range from $20.64 to $52.01 through 2035. The $31.50 average target implies a +96% move from current prices. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CAI price prediction for 2040 points to an average of $47.92 (low $28.95, high $84.70) — a potential gain of +198% on today's $16.09. Momentum favours further upside here.
In 2050, CAI is projected to trade between $47.99 and $178.62, averaging $91.57 — a potential gain of +469% from today's $16.09. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CAI today (≈ 62.150404 CAI) could be worth
$5,691.1
+$4,691.1 (+469%) by 2050 · US Dollar
Based on the average projected CAI price of $91.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAIwould be worth at today's price.
$1,000 invested in CAI on Jul 30, 2025 (≈ 33.898305 CAI) would be worth
$545.42
-$454.58 (-45.5%) today · 0.55× · US Dollar
Based on a CAI entry price of $29.5 vs. today's $16.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.65 | $1,028.12 | +2.8% |
| 1 month ago | $17.82 | $902.92 | -9.7% |
| 3 months ago | $18.47 | $871.14 | -12.9% |
| 6 months ago | $23.16 | $694.73 | -30.5% |
| 1 year ago | $29.5 | $545.42 | -45.5% |
| All time (1.1y) ago | $28 | $574.64 | -42.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAI forecast.
Our base-case forecast reaches $32.00 around 2040.
Implied market cap at $32.00: $9.05B
Over the multi-year horizon, the forecast paints a bullish arc after a neutral start. The 2026 average is $15.56 with a min of $14.55 and a max of $21.02 (ROI 0, sentiment NEUTRAL). By 2029 the average reaches $20.79 and the sentiment turns bullish, with the 2030 average at $23.34 and a 50% ROI.
The trajectory continues higher: 2031 average $26.21 (68.5% ROI), 2032 $27.61 (77.4%), 2033 $27.70 (78%), 2034 $27.79 (78.6%), 2035 $28.87 (85.6%). The longer horizon shows substantial upside with 2040 average $43.70 (180.8% ROI) and 2050 average $83.13 (434.3% ROI), with bullish sentiment in each of those years.
These are projected estimates and carry uncertainty. The forecast implies a rising price path and notable upside from 2029 onward, but investors should consider the inherent variance and that outcomes may differ from these projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $23.34 with a min of $16.09 and a max of $36.71. ROI is 50% and sentiment is BULLISH.
The forecast indicates a neutral stance in 2026 (avg $15.56, ROI 0%), followed by a bullish trend from 2029 onward, with the average rising to $23.34 by 2030 and ROI reaching 50% by 2030 and up to 434.3% by 2050. These are estimates and not guarantees.
Yes. The forecast lists a max of $50.87 in 2035, with higher later-year maxes of $83.21 in 2040 and $176.92 in 2050.
Current price is $15.56 per share and market cap is $4.4B.
The 30-day range runs from $12.72 to $19.03.
Caris Life Sciences, Inc. Community Discussion
0Share your Caris Life Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.